Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-01-07

Clinical Trial Update: A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase II study of bevacizumab plus sorafenib in metastatic breast cancer was terminated; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bevacizumab (bevacizumab)
  • Sorafenib (Sorafenib)

Snippet

Sponsor: Hoosier Cancer Research Network | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2016-01-07